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Abstract 
Allergen immunotherapy (AIT) is the only treatment option available for allergic patients with disease-modifying 
intention. Both efficacy and safety has been demonstrated for multiple trials in children, adolescents and adults. 
Though regulatory requirements for marketing authorization have been clearly outlined and an increasing number 
of high quality trials has been initiated, multiple concepts and details in study design may be further elaborated, 
harmonized and improved. An international group of experts in the field of AIT has thoroughly reviewed and dis-
cussed current concepts and provided an outlook on further improvement especially in the age group of children 
and adolescents. Emphasis of the group’s discussion as a basis for this article was put on (i) the regulatory background 
of marketing authorization of AIT products including the ‘Pediatric Investigational Plan’, (ii) patient reported outcomes 
and endpoints in AIT trials, (iii) considerations regarding the ‘minimal clinically important difference’, (iv) the role of 
placebo effects in AIT clinical trials and clinical routine and (v) the potential of mobile Health for future development 
of AIT. Current concepts in AIT have been optimized throughout the recent decades, but there remains room for 
improvement e.g., in the topics outlined in this article.
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Introduction
Throughout the recent 100 years after the inauguration of 
Allergen immunotherapy (AIT) [1] as the only treatment 
option available modulating the underlying immuno-
logical cause of the disease [2] and the first double-blind 
placebo-controlled trial on AIT for grass pollen aller-
gic patients performed in 1954 by Frankland et al. [3], a 
broad body of evidence for its efficacy and safety has been 
found subsequently in both pediatric and adult allergic 
patients [4–8]. An increasing number of clinical trials 
has been performed following the regulatory prerequi-
sites for marketing authorisation (MA) by authorities 
such as the European Medicines Agency (EMA) or the 
Center for Biologics Evaluation & Research (CBER) of 
the Food and Drug Administration (FDA) in the US [9]. 
Principles for study-design and evaluation of results have 
been outlined by authorities such as the “Guideline on the 
Clinical Development of Products for Specific Immuno-
therapy for The Treatment of Allergic Diseases (CHMP/
EWP/18504/2006)” of the EMA [10]. However, several 
methodological details have not been specified in these 
regulatory guidance and much emphasis has been put in 
the standardisation and improvement of trial design by 
the European Academy of Allergy and Clinical Immu-
nology (EAACI) (summarized in [11]). Moreover, still 
there is some room for improvement in general and in 
particular in clinical trials in the pediatric population 
[12]. Therefore, the following aims to outline current 
challenges in trial design in AIT in general with a special 
focus on the needs and specifications in the pediatric age 
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with Table 1 summarizing the current status and future 
needs of the examples of current concepts. As such, the 
review highlights recent discussion of a panel of experts 
in AIT and updates a series of scientific discussion [12].
The regulation of AIT products and Pediatric 
Investigational Plan
For MA, AIT products need to be approved by national 
competent authorities in different regions of the world 
including the European Union (EU) and the United States 
of America (USA) in general [9, 13]. While there is a wide 
heterogeneity in the demands for regulatory approval of 
AIT products—both within the EU and between EU and 
USA—the requirements for high quality clinical data for 
granting market access are a common feature and follow 
the guidelines on Good Clinical Practice (GCP) in the 
conduct of clinical trials [9, 14].
In the EU, the Clinical Trials Directive [15] imple-
mented GCP as a mandatory requirement for the con-
duct of state-of-the-art randomized, double-blind 
placebo-controlled (DBPC-) clinical trials and to docu-
ment them in an European database, similar to what 
is required in the US [9, 14]. Approval of AIT products 
involves the independent assessment as to whether or 
not a specific product shows a favorable risk–benefit pro-
file as the EU defines AIT products as medicinal products 
according to Directive 2001/83/EC [15], and with some 
exemptions AIT products need MA. A unique combina-
tion of national regulatory competent authorities in the 
EU work together in a network to regulate market access 
of medicinal products with the EMA, that is responsi-
ble for the coordination of the different MA procedures 
including the centralized procedure. To date, most AIT 
products use national MAs. Extending a national mar-
keting authorization to additional member states can be 
organized via the Mutual Recognition Procedure (MRP), 
in which the prior country acts as Reference Member 
State (RMS) and will provide assessment reports to sub-
sequent countries (Concerned Member States, CMS). 
The Decentralized Procedure (DCP) is now the preferred 
route for achieving MAs in multiple EU member states, 
as it allows faster decision and potential approval, as 
there is no requirement for a national authorization to 
precede the DCP [9, 14].
In the United States, the CBER of the FDA grants MAs 
of AIT products. To date, unmodified standardized and 
non-standardized aqueous aeroallergen extracts have a 
MA with the majority for subcutaneous AIT products 
[16]. In addition, sublingual tablets have also gained MA 
in the US [17]. To date, no formal guidance on clini-
cal development demands on AIT products in the US 
has been proposed by the US CBER with the conse-
quence that each product’s development is assessed and 
regulated individually [16]. Recent MA of sublingual tab-
lets has, however, followed similar prerequisites regard-
ing the clinical documentation as the guidance of the 
EMA.
Following the ‘Pediatric Investigational Plan’ (PIP), 
the Pediatric Committee (PDCO) of the EMA requests 
evidence for clinical efficacy from at least one longterm 
(3-year double-blind, placebo-controlled and 2-year 
blinded follow-up) study for an AIT product of the com-
pany’s portfolio [13, 18]. However, practical and ethi-
cal concerns arise from this regulatory demand as it has 
been shown extremely difficult for clinical trial centers 
to enroll a sufficient number of children for these trials 
[19], and long-term efficacy has been demonstrated for 
only a few products in this age group which would not 
be provided to children participating in such a trial [13, 
20]. Therefore, there is an urgent need for further devel-
opment of alternatives in AIT trial design in children and 
solutions should be made by all stakeholders involved 
such as pediatricians and allergists, regulatory authorities 
and manufacturers of AIT products [12, 13, 20].
In conclusion, regulatory prerequisites for recent MA 
have been comparable between Europe and the US and in 
principle are based on evidence for clinical efficacy and 
safety demonstrated in clinical trials following modern 
study-designs. In Europe, however, MA in the pediatric 
population will have to follow the ‘Pediatric Investiga-
tional Plan’ which raises concerns about the feasibility of 
these trials and further discussion.
Patient reported outcomes and clinical endpoints 
in AIT trials
Although many studies have included school children 
and adolescents in their pivotal trials, there are very few 
pediatric studies [6]. However, children may react differ-
ently from adults to AIT and there are no specific patient 
reported outcomes (PROs) for children. These considera-
tions are particularly important for pre-school children.
Clinical trials include primary outcome measures that 
provide the most clinically relevant and convincing evi-
dence [15]. As the methodology of choosing and assess-
ing outcome measures in AIT studies varies widely, an 
EAACI taskforce collected all available clinical measures 
of efficacy and made recommendations for their use in 
AIT trials [21]. The task force recommended a combined 
symptom and medication score as a harmonized and 
clinically justified primary outcome that has been fol-
lowed in an increasing number of recent AIT trials [22, 
23]. Notably, this combined proposed score better dis-
criminates between active and placebo treatment than 
the evaluation of symptom and medication scores sepa-
rately [24]. This score needs to be tested and compared 
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with other scores. Mobile Health (mHealth-) tools may 
be appropriate to validate such scores.
However, the expert panel of the EAACI clearly high-
lighted the unmet need of further validation of his pro-
posed endpoint especially in children where symptom 
and medication reporting is probably not the best meth-
odological option to detect clinical efficacy of interven-
tions as reporting is often given by parents [21], and 
further disadvantages of this approach can be argued for 
this age group, e.g., the fact that the amount of the con-
comitant rescue medication taken may not directly rep-
resent the level of the child’s symptom severity [12].
Secondary endpoints in AIT trials comprise other 
PROs e.g., subjective outcome measures such as individ-
ual symptom or medication scores, visual analogue scales 
(VAS), health related quality of life (HRQL) assessment, 
well days and severe days, global assessment, patient 
satisfaction and measures of rhinitis control [21, 25]. 
Some of those are even validated for pediatric and ado-
lescent patients as the Rhinoconjunctivitis Quality of Life 
Questionnaire (RQLQ) [26, 27]. Besides, the VAS score 
has been validated for adults [28], but not for children 
although the VAS is an instrument that could be easily 
implemented in pediatric trials and reporting would be 
facilitated in children as reported in one clinical trial [29].
Objective secondary endpoints also comprise assess-
ment by nasal or conjunctival provocation or by expo-
sure in allergen exposure chambers (AEC), extrapolating 
clinical effects of interventions to natural situation under 
natural allergen exposure, e.g., in the season [30–32]. 
Especially, trials in the latter would have a potential to 
reduce the high number of pediatric patients needed to 
fulfil regulatory requirements for marketing authoriza-
tion as demanded by the PDCO as outlined above [18], 
but apparently further technical and clinical validation 
in both pediatric and adult population is strictly needed 
before they will be accepted as pivotal for MA [10, 32].
In addition, measurement of specific IgG4 or block-
ing antibody activity are commonly used as secondary 
parameters in clinical trials in AIT. However, only the 
increase in blocking antibody activity has been associ-
ated with symptom improvement and further research of 
potential biomarkers in AIT has been highlighted as an 
important unmet need by the EAACI [33].
In conclusion, in spite of a consented position from 
academy for the preferred primary endpoint in AIT trials 
there remains a need to identify the best compositions of 
outcome measures in adult and pediatric AIT phase III 
trials. Ideally, such panels of endpoints may be limited 
to the CSMS as proposed by the EAACI in the combi-
nation with perhaps two confirming secondary measures 
besides the global evaluation of safety. However, clinical 
measures in pediatric trials may differ from adult study 
designs and an international harmonized standard espe-
cially for trials in this age population is warranted and 
should be elaborated by clinicians, regulatory and ethical 
authorities.
Minimal clinically important difference in AIT trials 
and clinical relevance
In line with regulatory prerequisites as the “Guideline on 
the Clinical Development of Products for Specific Immu-
notherapy for The Treatment of Allergic Diseases” of the 
EMA efficacy of AIT products has to be demonstrated 
in large clinical (so called pivotal) trials [10]. Because 
of the size of these studies, there is an obvious risk that 
small but statistically significant inpatient changes or 
between‐patient differences may be observed. The ques-
tion, however, remains as to whether such observations 
are relevant for patients and clinicians.
Calculating the minimal clinically important difference 
(MCID) could be a solution to overcome this require-
ment. The MCID has been defined as the smallest dif-
ference in the scores of a measure that is perceived by 
patient to be beneficial or harmful [21]. The MCID has 
been established mostly for a few secondary outcome 
measures such as the RQLQ (0.5) [34], the mini RQLQ 
(0.7) [35], the VAS [28] and the CARAT score for adults 
[36] and children [37]. In one AIT study the MCID of 
symptom scores has been calculated as 1.1–1.3 (rounded 
to 1) [38]. However, one has to bear in mind that the 
MCID represents a clinically relevant change in an out-
come measure, which implies a comparison between 
a baseline measurement and a measurement after 1 or 
more years of treatment. For instance, while a change in 
the RQLQ of 0.5 on a 7 points scale is clinically relevant, 
a difference of 0.5 between the active or placebo group 
does not constitute a similar meaning [21].
The inclusion of MCIDs in clinical trials has several 
advantages [39]. Not only is the patient’s perspective 
taken into account, clinicians are more able to interpret 
the results of a trial and to understand the success or the 
lack of success of an intervention. MCIDs help to esti-
mate the sample size and it is also easy to calculate the 
proportion of patients who achieve the MCID. From this 
proportion, the number needed to treat can be derived. 
Therefore, accepted ways to define and include clinical 
relevance will enhance the quality of clinical trials and 
contribute to a better positioning of new interventions 
into clinical practice. This is of utmost importance espe-
cially in clinical trials of AIT in the pediatric population 
with the aim to minimize the number of enrolled subjects 
due to ethical reasons.
This MCID described above has to be distinguished 
from the desired difference between placebo and 
active treatment of ≥ 20% stated by the World Allergy 
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Organization (WAO) [40] and by the “Global Allergy and 
Asthma European network” (GA2LEN) of the initiative 
“Allergy and its Impact on Asthma” (ARIA) [41]. How-
ever, this clinical minimal difference has not been deter-
mined with sufficient precision.
In contrast, for MA, the suggested guidance of the 
CBER branch of the FDA outlines two criteria that, in 
tandem, need to be met by a company submitting a Bio-
logical License Application (BLA) for a product to receive 
FDA regulatory approval. These include a desired dif-
ference between placebo and active treatment of ≥ 15% 
in the Total Combined Score (TCS) and evidence for a 
MCID that is further supported by clear separation of 
the active drug vs placebo group based on the 95% Upper 
Bound CI (≤ 10%) [42, 43].
In conclusion, MCID in clinical trials allows a suffi-
cient orientation of a medical intervention such as e.g. 
AIT regarding the clinical (relevant) efficacy. However, 
a thorough validation of the MCID for different clinical 
endpoints proposed is needed. This is in particular the 
case for AIT trials in children and adolescents in which 
a clinically justified MCID will improve the quality (and 
the feasibility) of the trial. As MCIDs are used in RCTs 
that may not reflect real life, observational studies should 
complement RCTs for real world evidence.
Placebo effects in AIT trials and considerations 
for trial design improvement
There is no generally accepted definition of when a 
treatment-intended substance is a placebo nor what is 
a placebo effect. In general, the definition by Brody and 
Moerman is widely used: “The placebo effect is most use-
fully defined as a positive healing effect resulting from the 
use of any healing intervention presumed to be mediated 
by the symbolic effect of the intervention for the patient.” 
[44]. However for use in clinical trials, the definition by 
Gøtzsche may be more useful: “The placebo effect is the 
difference in outcome between a placebo treated group 
and an untreated control group in an unbiased experi-
ment.” [45]. By that mean, in scientific studies placebo 
is considered to be a substance without pharmacologi-
cal effects itself which is provided to a control arm of 
patients. This aims to reduce any kind of unspecific psy-
chological and physical benefit an individual may gain 
through treatment which will bias the outcome of a trial 
[12]. In line with current regulatory demands, double-
blind placebo-controlled (DBPC) clinical trials remain 
the gold standard for quantifying the efficacy of medical 
interventions [10, 46].
This is in particular the case in AIT clinical tri-
als to ensure an unbiased reporting on its efficacy and 
tolerability by blinding of possible stratification of 
patients, reporting of outcomes as well as analysis and 
interpretation of data [10, 46]. Clinical endpoints, e.g., 
the CSMS of the EAACI [21] are predominantly sub-
jective which influences the robustness of these trials 
negatively. They are dependent on the subject and the 
investigator applying their judgment to score and grade 
their internal (subjective) feelings. Objectively measur-
able endpoints like laboratory results are less affected by 
both the investigator and the patient.
There is good evidence that placebo effects may be 
more marked in children than in adults although fewer 
placebo-controlled trials are conducted in children in 
general [47]. However, in the field of AIT there are no tri-
als published in the pediatric population with a baseline 
period (without intervention before randomization [48]) 
analyzed which would be helpful to indicate the impact 
and extent of placebo-effects in this age group.
In contrast to clinical trials with AIT in which results 
can be skewed due to the often pronounced placebo 
effect, these poorly understood, potentially neuro-
immunological, mechanisms [12] are highly effective 
and desired in the whole treatment concept of allergic 
patients in daily clinical routine in general.
In conclusion, placebo mechanisms play an inevitable 
role in medicine in general and in particular in the field 
of AIT. These effects have an important impact on the 
treatment effect in AIT which is desirable in the clini-
cal routine, but also dilutes signals from clinical trials. 
Therefore, further investigations and positions from aca-
demia such as a Task Force of the EAACI are of utmost 
importance.
mHealth in the AIT precision medicine approach
mHealth (mobile health) refers to the use of mobile 
and wireless devices to support healthcare delivery and 
improve health outcomes. mHealth has evolved from 
eHealth, the use of information and communication 
technology (ICT) for health services and information 
transfer. According to the World Health Organization 
(WHO) [49], mHealth can transform the face of health 
service delivery and may play a central role in future evo-
lution of “precision medicine” [50]. The rapid advances in 
mobile technologies and applications lead to a rise in new 
opportunities for the integration of mobile health into 
health and care. Many of these tools can be applied to 
the study and management of allergies. A recent review 
has provided examples of Apps used in allergic rhinitis 
[51]. These tools can be used for AIT in the selection and 
stratification of patients, the assessment of early benefits, 
evaluation of efficacy during the course and at the end of 
AIT, and in the follow-up after AIT has been terminated 
[52]. However, current mHealth tools cannot be used in 
young children as there are some ethical issues below 
15 to 18  years depending on the countries and further 
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development of smart devices in this age population 
would be preferable.
In line with current international guidelines in AIT, 
patients should be selected on the basis of the severity 
of the disease and on further prerequisites, e.g., a good 
treatment adherence [53–55]. This can easily be achieved 
using electronic diaries obtained by cell phones as dem-
onstrated in MASK-air®—a free online app developed for 
IOS and Andoid-systems by MACVIA-ARIA, an interna-
tional sentinel network for allergic rhinitis [56–58]. Such 
diaries should include the full list of medications. After 
a single year of survey, physicians can assess whether 
severe uncontrolled upper airway disease (SCUAD) [53] 
is present and could initiate AIT if (i) symptoms are 
associated with allergy season, (ii) adherence to pharma-
cologic treatment is achieved, (iii) the duration of uncon-
trolled symptoms was long enough and (iv) an impact 
on work or school productivity was observed. Moreover, 
asthma and eye symptoms can be recorded, as in MASK-
air® [57] and other Apps allowing to evaluate the role of 
multi-morbidity [59]. The same approach can be pro-
posed for the follow up of patients on AIT to assess its 
efficacy as suggested by a panel of international experts 
in an AIT Position Paper [21, 52].
An electronic clinical decision support system (CDSS) 
is a health information technology (IT) system designed 
to assist clinicians and other health care professionals 
in clinical decision-making. In medicine, CDSSs have 
become a major topic in artificial intelligence. The AR 
algorithm has been digitalized in tablets for health care 
professionals [60]. A CDSS can reduce the burden that 
exponentially-expanding clinical knowledge and care 
complexity places on clinicians, other health care profes-
sionals or patients [61]. Embedding the results of Apps in 
and e-CDSS will help physicians to decide when to start 
and stop AIT.
In conclusion, the use of mobile and wireless devices is 
increasingly enhancing healthcare delivery and improv-
ing health outcomes (mHealth). Apps may be used for 
optimization of AIT by the selection and stratification of 
patients, the assessment of onset of action, evaluation of 
efficacy during the treatment course and after cessation. 
As such this technology will enable a better documenta-
tion of treatment effects in pediatric trials assumed that 
smart technical solutions can be further developed for 
this age group.
Conclusion
Regulatory authorities request a clinical documenta-
tion of efficacy and safety for marketing authorization 
following guidance such as e.g. the “Guideline on the 
Clinical Development of Products for Specific Immuno-
therapy for The Treatment of Allergic Diseases (CHMP/
EWP/18504/2006)” of the EMA. However, some of 
methodological common standards in AIT clinical trial 
design need further exploration and thorough consid-
eration. This review reports scientific discussion held 
by German, French, Dutch and US American experts 
in the field of AIT regarding improvement of concepts 
in AIT trial design. Emphasis is put on the regulatory 
situation with a special focus on the “Pediatric Inves-
tigational Plan” for AIT, on patient reported outcomes 
and clinical endpoints in both adult and pediatric trials, 
on the importance of further investigation of the “mini-
mal clinically important difference” in the evaluation 
of clinical efficacy as demonstrated in AIT trials, on 
the role of the placebo effect as one component of the 
whole treatment effect, and the potential of mHealth 
for further elaboration of the AIT benefit in the era of 
precision medicine. Pediatric specifications are empha-
sized for all of these concepts. Future work may also 
focus on additional key research areas in this particular 
age-group such as e.g., trial designs for prevention of 
allergies, polysensitized children/adolescents, asthma 
endpoints etc. A better understanding and improve-
ment of these concepts are key in aiming to confirm 
AIT as the only-disease modifying treatment option 
available especially in children.
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